MedTrace Logo

Gene Expression in Patients With Advanced or Metastatic Colorectal Cancer Receiving Bevacizumab

NCT00897754 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2017-05-19

No results posted yet for this study

Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors understand how patients respond to treatment.

PURPOSE: This laboratory study is looking at gene expression in patients with advanced or metastatic colorectal cancer receiving bevacizumab.

Conditions

Interventions

GENETIC

gene expression analysis

GENETIC

protein expression analysis

GENETIC

reverse transcriptase-polymerase chain reaction

OTHER

immunoenzyme technique

OTHER

immunohistochemistry staining method

OTHER

immunologic technique

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • David Bates, PhD · Bristol Heart Institute at University of Bristol

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-24
Primary Completion
2009-02-01
Completion
2009-02-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00897754 on ClinicalTrials.gov